GLP-1 Telehealth Prescribing: Online Clinics
GLP-1 Access & Economics
16.6% body weight lost
A 655-patient retrospective cohort found semaglutide prescribed entirely through telehealth produced mean weight loss of 16.6%, comparable to clinical trial results.
Tchang et al., Obesity, 2026
Tchang et al., Obesity, 2026
View as imageOnly 1.8% of adults clinically eligible for GLP-1 receptor agonists actually start them, according to an analysis of 319,949 patients in the OneFlorida+ health network.[1] That gap between who could benefit and who receives treatment has created the market conditions for telehealth platforms to become one of the fastest-growing channels for GLP-1 prescribing. Companies like Ro, Hims & Hers, and LifeMD now prescribe semaglutide and tirzepatide to millions of patients through entirely remote encounters. The evidence for whether this model works, and where it fails, is beginning to emerge. For a broader look at the economic forces shaping access to these drugs, see the cost-effectiveness analysis of GLP-1s.
Key Takeaways
- Only 1.8% of 319,949 eligible adults initiated GLP-1 anti-obesity medications, with Black patients (aOR 0.87) and Medicaid enrollees (aOR 0.69) significantly less likely to start treatment (Radwan et al., 2025)
- A 966-patient DTC telemedicine study found 85.6% lost more than 2 kg in 50 days on liraglutide, with 94.1% treatment adherence (Gratzke et al., 2025)
- Semaglutide prescribed via telehealth produced 16.6% mean body weight reduction in 655 patients, matching the 14.9% from the STEP 1 clinical trial (Tchang et al., 2026; Wilding et al., 2021)
- Among 57,975 GLP-1 users, those who engaged with a digital health app lost 9% versus 5.9% at 3 months, a large effect size of Cohen d = 0.89 (Johnson et al., 2025)
- Compounded GLP-1s showed 2.35 times higher hospitalization odds and 49 times higher preparation error rates compared to FDA-approved products in FAERS data (McCall et al., 2026)
- In a remote semaglutide-supported program, 60% of participants dropped out before 12 months, though completers lost 19.1% of body weight (Richards et al., 2025)
The Access Problem Telehealth Is Trying to Solve
The chasm between GLP-1 eligibility and actual treatment uptake is enormous. Radwan et al. (2025) analyzed electronic health records from 319,949 adults who met clinical criteria for anti-obesity medication (BMI of 30 or above, or 27 to 29.9 with at least one comorbidity) and found that only 5,759 (1.8%) initiated a GLP-1 receptor agonist between 2015 and 2024.[1] The disparities within that already small number are stark. Black patients had 13% lower odds of initiation (adjusted odds ratio 0.87), Hispanic patients had 16% lower odds (aOR 0.84), Medicaid enrollees had 31% lower odds (aOR 0.69), and uninsured patients had 19% lower odds (aOR 0.81) compared to their White, privately insured counterparts.
These numbers represent a massive unmet demand. Traditional barriers include cost (GLP-1s list at over $1,000 per month in the US), limited insurance coverage, geographic distance from obesity medicine specialists, and the fact that 92.5% of primary care providers report using clinical judgment rather than guidelines when treating obesity. Telehealth platforms have positioned themselves as a solution to at least some of these barriers, offering virtual consultations, home delivery, and in many cases, access to compounded versions of semaglutide and tirzepatide at significantly lower prices. For details on insurance coverage challenges, see our dedicated article.
What the Outcome Data Shows
Short-Term Results Are Promising
The first large-scale study of DTC telemedicine GLP-1 prescribing came from Gratzke et al. (2025), who analyzed data from 966 patients who received liraglutide prescriptions through a DTC platform between August 2022 and April 2024.[2] Most patients (70%) had long-standing obesity, and 88.9% were new to GLP-1 therapy. After 50 days, 85.6% reported losing more than 2 kg, with an average loss of 4.9 kg. Treatment adherence was 94.1%, and despite 39.8% reporting adverse events (primarily gastrointestinal), 86.4% wanted to continue treatment.
These numbers are encouraging, but the 50-day follow-up window is short. The real test of any weight management approach is whether patients maintain results at 6 and 12 months.
Telehealth Can Match Clinical Trial Outcomes
The strongest evidence that telehealth-prescribed GLP-1s produce comparable weight loss to clinical trials comes from Tchang et al. (2026), published in Obesity. This retrospective cohort study analyzed data from Ro, a major telehealth platform, examining 655 patients treated with semaglutide entirely through telehealth.[3] Mean body weight reduction was 16.6% (SD 7.5%). The most common adverse events were nausea and vomiting (37.3%) and constipation (15.6%), with no new safety signals observed.
For comparison, the STEP 1 trial (Wilding et al., 2021), which remains the benchmark for semaglutide obesity data, found 14.9% mean weight loss with semaglutide 2.4 mg versus 2.4% with placebo over 68 weeks in 1,961 participants.[4] That the telehealth cohort achieved similar (even slightly higher) weight loss suggests the treatment setting may matter less than the drug itself, though differences in patient selection, measurement methods, and follow-up duration make direct comparisons imprecise.
The Dropout Problem
The most sobering data on telehealth GLP-1 programs comes from Richards et al. (2025), who evaluated a remotely delivered semaglutide-supported weight management program in the UK (Second Nature).[5] Of 341 participants at baseline, only 39.6% maintained an active subscription at 12 months. Among the completers with weight data, results were impressive: mean weight loss of 20.0 kg (19.1% of starting weight), with 77.7% achieving at least 10% weight loss and 61.5% achieving at least 15%.
But the 60.4% dropout rate is the central finding. Weight data at 12 months was available for only 52.5% of the baseline cohort, meaning the reported outcomes likely overestimate population-level effectiveness. The reasons for discontinuation mirror what Naveed et al. (2025) found in their survey of 1,659 GLP-1 users managed in a virtual setting: treatment costs, unmet weight loss expectations, and side effects drove discontinuation, while 55% had attempted weight loss for over a decade before starting GLP-1 therapy.[6] Stigma and affordability were notable deterrents even among those who found the medication effective at reducing "food noise."
Digital Engagement Changes Outcomes
Whether patients simply receive a prescription through telehealth or actively engage with digital health tools alongside their medication appears to matter substantially. Johnson et al. (2025) published the largest study to date on this question, analyzing 57,975 participants using semaglutide or tirzepatide through the Voy digital health platform in the UK.[7]
Participants classified as "engaged" (attending coaching sessions, tracking weight regularly, and using the app frequently) lost 9.0% of body weight at 3 months versus 5.9% for non-engaged users, a difference of 3.1 percentage points with a Cohen d effect size of 0.89, indicating a large effect. At 5 months, engaged participants lost 11.5% versus 8.0%. Tirzepatide users achieved greater weight loss than semaglutide users overall (13.9% versus 9.5% at 5 months).
The study cannot establish causation. Patients who engage more with digital tools may be inherently more motivated and would have lost more weight regardless. But the magnitude of the difference (a 53% greater weight loss at 3 months) suggests that telehealth programs delivering medication alone, without structured behavioral support, may be leaving meaningful results on the table. This has direct implications for how compounded semaglutide versus brand Wegovy programs are structured, since compounded prescribers vary widely in the level of clinical support they provide.
The Compounded Drug Question
A significant portion of telehealth GLP-1 prescribing has involved compounded versions of semaglutide and tirzepatide, which are produced by compounding pharmacies at lower cost than brand-name products. The regulatory landscape here shifted dramatically in 2025 and 2026.
Safety Signals From FAERS Data
McCall et al. (2026) analyzed the FDA Adverse Event Reporting System (FAERS) from 2018 to 2024, comparing 707 reports involving compounded GLP-1 products against 80,371 reports for non-compounded versions.[8] The findings raise concern:
- Compounded products had 2.84 times higher reporting odds for abdominal pain, 1.59 times for diarrhea, and 1.27 times for nausea
- Hospitalization odds were 2.35 times higher for compounded products
- Preparation errors had a reporting odds ratio of 48.92, contamination 19.00, and compounding/manufacturing issues 8.51
- A 6.34 times higher reporting odds ratio for suicidality was observed, though the absolute numbers were small and the signal requires further investigation
FAERS is a passive surveillance system, meaning these reporting odds ratios reflect what was reported, not necessarily true incidence rates. Products under scrutiny tend to generate more reports. Still, the preparation error and contamination signals are consistent with the fundamental challenge of compounding: vials and syringes lack the safety features of manufacturer prefilled pens.
Dosing Errors in Practice
Lambson et al. (2023) documented the practical consequences of compounded semaglutide in a case series of administration errors reported to a poison control center.[9] Two of three patients self-administered 10-fold dosing errors. The errors stemmed from the use of syringes not designed for semaglutide, leading to confusion between dosing units (milliliters, units, milligrams). One patient received their vial from a compounding pharmacy with no pharmacist counseling on proper administration. All three experienced prolonged nausea, vomiting, and abdominal pain, with symptoms lasting days.
These are not theoretical risks. Prefilled manufacturer pens are designed to prevent exactly this type of error. When compounding pharmacies dispense vials with generic syringes, they remove a safety layer without consistently replacing it with adequate patient education.
The Regulatory Crackdown
In February 2026, the FDA sent warning letters to 30 telehealth companies over claims made about compounded GLP-1 drugs on their websites. The warnings focused on false or misleading claims, including implying sameness with FDA-approved products and obscuring product sourcing. Congress also introduced the SAFE Drugs Act of 2025, expanding FDA oversight of compounded GLP-1 drugs and telehealth providers.
The legal landscape has narrowed significantly. Semaglutide and tirzepatide are no longer on the FDA drug shortage list, which was the primary legal basis for compounding these medications at scale. Under Sections 503A and 503B of the Food, Drug, and Cosmetic Act, compounding without a shortage listing requires patient-specific prescriptions with documented medical necessity, a far more restrictive standard than the mass-market model many telehealth companies had adopted.
Who Is Prescribing Through Telehealth
The prescribers behind telehealth GLP-1 platforms are not always obesity medicine specialists. A STAT News investigation in 2024 found that the medical groups powering telehealth GLP-1 prescribing ranged from board-certified obesity medicine physicians to general practitioners with limited obesity training. A survey by the Medical Professional Liability Association found that 67% of primary care physicians expressed concern about patients accessing GLP-1 prescriptions through third-party telehealth, citing risks of overprescribing (56%) and compromised continuity of care (50%).
The concern is not that telehealth providers are incompetent. It is that the DTC model, by design, separates the prescribing encounter from the patient's ongoing medical history. Some 77% of PCPs reported conducting thorough physical evaluations before prescribing GLP-1s, assessing for comorbidities like diabetes, cardiovascular disease, and hypertension. Telehealth prescribers may not have access to this context, relying instead on patient-reported health questionnaires.
The Novo Nordisk partnerships with Hims & Hers, LifeMD, and Ro to distribute FDA-approved Wegovy at $499 per month represent an attempt to bring telehealth prescribing within the brand-name, FDA-approved framework. Whether these partnerships shift the market away from compounded products remains to be seen.
What the Evidence Supports and What It Does Not
The evidence for telehealth GLP-1 prescribing is strongest in three areas:
Telehealth can deliver trial-level weight loss. The Tchang et al. data showing 16.6% body weight reduction via telehealth aligns with the 14.9% from STEP 1.[3][4] For patients who cannot access in-person obesity specialists, which is most eligible patients, telehealth removes a real barrier.
Digital behavioral support amplifies outcomes. The Johnson et al. study of 57,975 patients demonstrated that engagement with digital health tools during GLP-1 therapy increases weight loss by approximately 3 percentage points at 3 months.[7] Telehealth platforms that pair prescriptions with structured coaching and tracking appear to produce better results than those offering medication alone.
The access gap is real. With only 1.8% of eligible patients starting GLP-1 therapy through traditional channels, and with significant racial and socioeconomic disparities in that already tiny number, the argument that telehealth can democratize access has empirical backing.[1]
The evidence is weakest in three areas:
Long-term retention is poor. The 60% dropout rate from the Richards et al. study suggests that telehealth programs struggle to keep patients engaged beyond the initial months.[5] This is not unique to telehealth; in-person weight management programs also face high attrition. But the question of whether remote care exacerbates the problem or merely mirrors it is unanswered.
Compounded product safety is concerning. The FAERS data from McCall et al. shows higher adverse event reporting and substantially higher rates of preparation and contamination errors for compounded products.[8] These findings are consistent with documented dosing errors from Lambson et al.[9]
No randomized trials compare telehealth versus in-person prescribing. All existing evidence is observational and retrospective. The patients who choose telehealth may differ systematically from those who visit clinics in person, making it difficult to attribute outcomes to the delivery model itself.
For the broader context of how GLP-1 drug costs affect access across all channels, see the complete cost breakdown of GLP-1 drugs. For a look at the supply chain dynamics driving patients to telehealth in the first place, see our coverage of the GLP-1 shortage explained.
The Bottom Line
Telehealth GLP-1 prescribing addresses a genuine access crisis: only 1.8% of eligible patients start these medications through traditional channels, with significant racial and socioeconomic disparities. Early outcome data suggests telehealth-prescribed semaglutide can produce weight loss comparable to clinical trials, and digital engagement tools amplify results. The tradeoffs are high dropout rates, safety concerns with compounded products, and an evolving regulatory environment that is restricting the compounding model that made many of these platforms viable.